Alnylam Pharmaceuticals (ALNY) successfully completed a Phase 3 clinical trial, APOLLO, assessing RNAi therapeutic Patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy, and met its primary endpoint.
Gets Analyst love:
|Cowen and Company||Reiterates||Outperform||$93.00 -> $117.00|
|JMP Securities||Raises Target||Outperform||$101.00 -> $128.00|
|Needham & Company LLC||Raises Target||$85.00 -> $125.00|
|Piper Jaffray Companies||Reiterates||Overweight||$110.00 -> $116.00|
|Stifel Nicolaus||Reiterates||Hold||$56.00 -> $83.00|
Check out more such briefs in our Daily Pharma Scoop at SeekingAlpha Marketplace.